Tarsus announced projections for $685M-$705M in net product sales for XDEMVY by 2026, while also moving forward with its acquisition of Alkeus.

A man in Tarsus, Turkey, killed his former wife and five other individuals before committing suicide when surrounded by gendarmerie. An 11-year-old boy reportedly called the police after witnessing his mother being shot.

Turkey was shaken by a severe gun attack in the Tarsus district of Mersin province, where four people died and eight were injured after a series of armed assaults.

A summary of Tarsus Pharmaceuticals, Inc.'s first-quarter 2026 earnings call, detailing key financial results and business updates.

Oppenheimer has increased its price target for Tarsus Pharmaceuticals, Inc. (TARS) to $105, maintaining an Outperform rating on the stock.

Tarsus Pharmaceuticals has entered the retina market through a new deal involving iRenix, thereby adding IRX-101 to its development pipeline.

Four people were killed and eight others injured in a shooting attack at a restaurant in Tarsus, near Mersin, Turkey. A 17-year-old suspect reportedly carried out the attack.

An article from Rzeczpospolita discusses Paul of Tarsus, using a metaphor of a 'complete athlete' to describe his journey and significance.

A summary of Tarsus Pharmaceuticals, Inc.'s earnings call for the fourth quarter of 2025 has been released.

Tarsus has completed the acquisition of iRenix Medical for $75 million, thereby gaining control of the late-stage eye care asset IRX-101.

A man reportedly shot and killed his wife and at least five other people in the Turkish city of Tarsus, injuring eight others before fleeing the scene.

Several companies, including Root, Adient, TaskUs, and Maximus, have released their earnings call transcripts or summaries for the first or second quarter of 2026. These reports provide financial updates and insights into their recent performance.

Tarsus Pharma's stock saw a 20% increase following an insider's sale of $839,000 in RSU-linked trades.

Tarsus expects 2026 sales between $670 million and $700 million, with its drug XDEMVY projected to reach over $2 billion in potential sales as its pipeline advances.